Archive: March 2023

Management of Toxicities Associated With Immune Checkpoint Inhibitors

Abstract: Immune-related adverse events (irAEs) encompass a diverse range of toxicities following treatment with immune checkpoint inhibitors (ICIs), each with distinctive symptoms, severities, and outcomes. irAEs […]

CAR T-Cell Therapy for CLL: A New Addition to Our Treatment Toolbox?

Abstract: Treatment of high-risk chronic lymphocytic leukemia (CLL) has undergone a revolution in recent years with the introduction of novel agents. Bruton kinase inhibitors (BTK) inhibitors, […]

Factors Guiding Selection of Treatment in Metastatic Colorectal Cancer

H&O  What factors guide selection of treatment in metastatic colorectal cancer? LS  Metastatic colorectal cancer is a very broad area that requires an individualized approach to […]

Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer

H&O  What types of novel endocrine therapies are being developed for use in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer? EH  […]

New Evidence for Neoadjuvant Therapy in Advanced Melanoma

H&O  What was the history behind the SWOG S1801 study that you presented at the most recent European Society for Medical Oncology congress? SP  The benefits […]

The Use of Biomarkers in Early-Stage NSCLC

H&O  Should patients with early-stage non–small cell lung cancer (NSCLC) get biomarker testing of their surgical specimens? JK  A few years ago, I would have said […]

Zandelisib and B-Cell Lymphomas

H&O  How does zandelisib work?  AZ  Zandelisib is a phosphoinositide 3-kinase delta (PI3K-δ) inhibitor with a long half-life. PI3K comes in multiple isoforms, including alpha, beta, […]

Letter From the Editor: Clinical Research Under Siege

Over the last three years, many of us who work in clinical research have felt an increased strain on our fragile infrastructures. I am tempted to […]

Back to Archive